Form 4 for IDYA IDEAYA Biosciences, Inc.
Accepted 2024-02-12 00:00:00 ET · period of report 2024-02-08 · accession 0001610717-24-000053 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2024-02-12 | 2024-02-08+ | IDYA | Hata Yujiro S | Pres, CEO, Dir | M - OptEx | $4.31 | +99.4K | 701.4K | +17% | +$428.3K |
| DMT | 2024-02-12 | 2024-02-08+ | IDYA | Hata Yujiro S | Pres, CEO, Dir | S - Sale+OE | $45.24 | -99.4K | 677.9K | -13% | -$4.50M |
| DMT | 2024-02-12 | 2024-02-08+ | IDYA | Hata Yujiro S | Pres, CEO, Dir | M - OptEx | $0.00 | -99.4K | 248.0K | -29% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-02-08 | M | A | 75,815 | $4.31 | 753,702 | D | — | — | |
| 2 | Common | Common Stock | 2024-02-08 | S | D | 75,815 | $45.15 | 677,887 | D | — | — | (F2) This transaction was executed in multiple trades in prices ranging from $45.00 to $45.36, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
| 3 | Common | Common Stock | 2024-02-09 | M | A | 23,557 | $4.31 | 701,444 | D | — | — | |
| 4 | Common | Common Stock | 2024-02-09 | S | D | 23,557 | $45.54 | 677,887 | D | — | — | (F3) This transaction was executed in multiple trades in prices ranging from $45.01 to $45.82, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
| 5 | Derivative | Stock Option (right to buy) | 2024-02-09 | M | D | 23,557 | $0.00 | 224,454 | D | $4.31 · — to 2028-02-26 | 23,557 Common Stock | (F4) The shares subject to the option are fully vested and exercisable. |
| 6 | Derivative | Stock Option (right to buy) | 2024-02-08 | M | D | 75,815 | $0.00 | 248,011 | D | $4.31 · — to 2028-02-26 | 75,815 Common Stock | (F4) The shares subject to the option are fully vested and exercisable. |